P2-008: Influence of common glutathion-S-transferase and DNA repair variant alleles on p53 function: relation to lung cancer risk and progression  by Gervas, Polina et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS484
P2-006 BSTB: Cancer Genetics Posters, Tue, Sept 4 
Homeobox gene HOP has a potential tumor suppressive activity in 
human lung cancer
Chen, Yuan Pacyna-Gengelbach, Manuela Niesporek, Silvia 
Deutschmann, Nicole Petersen, Iver 
Institute of Pathology, University Hospital Charite, Berlin, Germany
The homeobox containing gene LAGY (Lung Cancer Associated Gene 
Y Genbank accession Nr. AF454763), also named Hop (Homeodo-
main only protein), was identiﬁed in the developing heart and lung 
where it functions downstream of Nkx2.5 and Nkx2.1 to modulate 
cardiac and lung gene expression. Previously, we found that LAGY 
was downregulated in lung cancer cell lines and primary lung tu-
mors and the downregulation was linked to higher tumor grading. In 
this study, we constructed an expression vector containing the full-
length cDNA of LAGY and transfected it into a lung cancer cell line 
H2170. Stable transfection led to an increased expression of LAGY 
which was conﬁrmed by Northern blot and Western blot analysis. 
LAGY positive transfectants remarkably reduced the growth rate as 
well as the ability of anchorage-independent growth in soft agar, and 
moreover, suppressed the tumor formation in immune-deﬁcient nude 
mice compared to mock transfectant and parental cells. Transient 
transfection of Nkx2.1 into H2170 resulted in the overexpression of 
LAGY, and correspondingly, siRNA silencing of Nkx2.1 reduced the 
expression of LAGY in a lung cancer cell line H2228, the only lung 
cancer cell line expressing LAGY we found so far. Treatment with a 
differentiation modulating agent 5-bromodeoxyuridine (BrdU) led to 
restoration of LAGY expression in a small cell lung cancer cell line 
H526B. However, knockdown of LAGY expression in H526B by RNA 
interference (siRNA) neither caused any decreased expression in lung 
epithelial differentiation markers nor any changes in cell morphology, 
implicating that LAGY might not act as a differentiation trigger in lung 
cancer. In 29 paired primary lung tumors, loss of heterozygosity (LOH) 
analysis was performed by using three microsatellite markers D4S189, 
D4S231 and D4S392 around the region of chromosome 4q12 where 
LAGY locates. LOH was only found in 4 out of 23 cases (17.4 %), 
indicating that allelic loss is a rare genetic event not responsible for the 
downregulation of LGAY in lung cancer. Taken together, our data sug-
gest that LAGY is a potential tumor suppressor involved in lung cancer 
differentiation, and possibly functions downstream of Nkx2.1.
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Background: Non-small cell lung carcinomas (NSCLC) are broncho-
genic carcinomas characterized by their intrinsic resistance to chemo-
therapy and mechanisms of this clinical resistance are poorly known. 
The Multidrug Resistance Protein (MRP) family belong to the ATP 
binding cassette super family of transport proteins, which play a physi-
ological role in defence against toxic compounds including carcino-
gens. Some MRPs have been shown to confer resistance to anticancer 
agents in various in vitro models. 
Methods: In order to investigate the possible role of MRP1 and -3 
in clinical drug resistance, protein and gene expression was analysed 
using, respectively, immunohistochemistry and RT-PCR (Light-cycler, 
Roche®) on tumoral tissue sample from patient who underwent surgery 
for localised NSCLC.
Results: 13 tumorals frozen samples were used, 8 were adenocarcino-
mas and 5 were squamous carcinomas. Regarding protein expression 
for MRP1 and -3, 10 samples were considering negative for MRP1 
and 8 negative for MRP3, proteins expression was independent in 
each sample and according to histological sub-group. Regarding gene 
expression, all samples have positive expression for each gene; relative 
quantities for each gene were variable in each sample. No pattern of 
expression was found according to sample or histological sub group.
Relation between protein and gene expression was then analyzed. No 
relation was found for MRP1, all samples had positive gene expres-
sion and only 3 samples had a positive staining for MRP1. Analysis 
for MRP3, showed that a relation between protein and gene expression 
could exist. Positive staining for MRP3 were found in samples were 
gene expression were higher.
Conclusions: Gene and protein expression in tumoral non small cell 
lung cancer sample is not found for MRP1 and seems to be positive 
for MRP3, depending on a gene expression threshold. More samples 
need to be analyzed to conﬁrm those results and survey for patient who 
underwent adjuvant chemotherapy is already studied. 
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Recent evidence suggest that polymorphism such as genes as GST 
M1 and T1, p53 and XRCC1, playing a critical role in neutralization 
of chemical carcinogens, cell-cycle arrest, DNA repair and apoptosis 
may provide additional risk for lung cancer. In fact, many studies have 
evaluated the relationships between polymorphism of the glutathion-S-
transferase or DNA repair genes with the p53 protein function, but the 
results are equivocal. 
Background: Bronchial epithelium is exposed to risk of damage by 
polycyclic aromatic hydrocarbons from a tobacco smoke or endog-
enous metabolic agents which can play a role of pro-carcinogens. Pres-
ents of the “null” genotypes of glutathion-S-transferase genes leads to a 
total loss of enzymatic activity, high level of activated carcinogens and 
DNA- adducts formation: benzo(a)pyrene diol epoxide-DNA-adducts 
may potentiate the mutation of p53 gene, involving in cell cycle arrest 
to allow repair DNA damage. p53 and XRCC1 genes has been identi-
ﬁed as necessary components of the base excision repair for removing 
of spontaneous mutations in the cells. Numerous SNPs are located in 
exons or promoter regions of XRCC1 gene may alter the efﬁciency of 
the repair process. 
Methods: Polymorphism of the GSTT1, GSTM1, p53 and XRCC1 
genes was evaluated in 170 lung cancer patients and 200 healthy donors. 
GSTM1 and GSTT1 genotypes was determined by a multiplex PCR. 
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p53 genotypes at the three polymorphic sites (intron 3,exon 4 codon 72, 
intron 6) and XRCC1-Arg399Gln exon 10 polymorphism was deter-
mined by a PCR-RFLP. Mutant p53 protein expression was detected in 
tumor of lung cancer by using immunohistochemical staining. 
Results: We found that aberrant p53 protein expression is positively 
correlated (p=0,03,CI95%=1,37-5,83) with null-genotypes of GSTM1 
and GSTT1 genes in lung cancer patients. Also, we found that function-
ally inactive genotypes of GST M1( p=0,023, CI95% =1,11-4,42) and 
GSTT1( p=0,077, CI95% =0,94-3,6) genes are associated with lymph 
node involved lung cancer patients.
In parallel, we observed that lung cancer risk was signiﬁcantly in-
creased at the presence of Gln/Gln genotype (homozygous on mi-
nor-variant allele) of XRCC1 gene ( p=0,03, CI95%= 1.00-3.49) and 
decreased for individuals bearing Arg/Gln genotype (p=0,01, CI95%= 
0.34-0.94). To further explore the role of XRCC1 and p53 genes 
polymorphism in lung cancer risk we found high frequency of the 
combination XRCC1/p53(in3/ex4/in6) [M/M]/[W/W-W/W-W/W] from 
lung cancer patients against control subject (12% and 4%, respectively, 
p=0,05,CI95%=1,00-10,32).
Discussion: Our results suggest the role of null-GST genes in lung 
cancer progression. We found that Gln/Gln genotype of XRCC1 gene 
at the presence of combination wild -type genotypes of p53 gene may 
be considered as important genetic event in the development of lung 
cancer, because the XRCC1-399Gln allele is associated with lower 
efﬁciency of DNA repair and play critical role in the successful DNA 
repair.
Conclusion: Data obtained suggest that the polymorphism in metabolic 
enzymes (GSTT1 and GSTM1) and DNA repair (XRCC1) genes may 
affect risk and progression of lung cancer due to their inﬂuence on p53 
function. 
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Background: The organic anion transporting polypeptide (OATP) 1B1 
is a drug uptake transporter located at the basolateral membrane of 
hepatocyte. Here we investigated the association of single nucleotide 
polymorphisms (SNP) in the SLCO1B1 gene encoding for OATP1B1 
with irinotecan-pharmacokinetics, toxicity and survival of patients with 
advanced non-small cell lung cancer (NSCLC). 
Methods: Peripheral blood samples from 81 NSCLC patients prospec-
tively enrolled in a phase II study of irinotecan and cisplatin chemo-
therapy were used for genotyping SLCO1B1 -11187G>A, 388A>G, 
and 521T>C. 
Results: Patients with the 521C allele showed a trend for higher SN-38 
AUC (p=0.054) compared to those without this allele. When haplo-
types were assigned, patients with at least one *15 haplotype (contain-
ing 388A>G and 521T>C variants) showed signiﬁcantly higher SN-38 
AUC than noncarriers (p=0.009). The most common severe toxicity 
was NCI-CTC grade 4 neutropenia (G4N), which occurred in 22 (27%) 
patients. Patients with 521C allele showed higher incidence of G4N and 
lower delivered dose of irinotecan (p=0.047) than those without this 
allele. Patients with the -11187A allele also showed a trend for higher 
G4N (p=0.057) and lower delivered dose of irinotecan (p=0.029). 
Grade 3 diarrhea was developed in 8 (10%) patients those with the 
388GG genotype (p=0.046). In survival analysis, patients with *1b/*1b 
diplotype showed worse overall survival than others (p=0.004), which 
was retained in multivariate analysis. 
Conclusions: These ﬁndings suggest that OATP1B1 variants are 
involved in transporting SN-38 and highly predictive for toxicity and 
prognosis of NSCLC patients treated with irinotecan-based chemo-
therapy.
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Background: To investigate whether ABCB1, ABCC2, and ABCG2 
genetic polymorphisms affect pharmacokinetics (PK) of irinotecan 
and treatment outcome of patients with advanced non-small cell lung 
cancer (NSCLC).
Methods: Blood samples from 107 NSCLC patients treated with iri-
notecan and cisplatin chemotherapy were used for genotyping ABCB1 
(1236C>T, 2677G>T/A, 3435C>T), ABCC2 (-24C>T, 1249G>A, 
3972C>T), and ABCG2 (34G>A, 421C>A) polymorphisms. Geno-
types were correlated with irinotecan PK, toxicity, tumor response, and 
survival.
Results: Among 8 polymorphisms, 3435TT and 2677TT were associ-
ated with SN-38G AUC and SN-38G clearance. When haplotypes are 
assigned, 2677TT/3435TT carriers showed signiﬁcantly lower SN-38G 
AUC (P=0.006), whereas, 2677GG/3435CC carriers showed signiﬁ-
cantly higher SN-38 AUC (P =0.039). These ﬁndings suggest that 
2677TT and 3435TT variants are associated with higher efﬂux activity. 
In toxicity, the 2677G/T or A was associated with grade 4 neutropenia. 
The 2677GG carriers showed signiﬁcantly lower absolute neutrophil 
count during the 1st cycle (p=0.012) as well as entire course of chemo-
therapy (p=0.042). The 3435TT was associated with higher frequency 
of grade 3 diarrhea (p=0.047). In tumor response, ABCC2 -24TT and 
3972TT genotypes were associated with higher response rates (p=0.031 
and 0.046, respectively) and longer progression-free survival (p=0.035 
and 0.038, respectively), which was sustained in haplotype analysis. 
Conclusions: Speciﬁc polymorphisms of ABCB1 and ABCC2 can 
inﬂuence the disposition and tumor response to irinotecan by regulating 
transporter activity. These ﬁndings may help to individualize irinote-
can-based chemotherapy in patients with advanced NSCLC.
